Viatris Launches Hulio (biosimilar, adalimumab) in Canada

 Viatris Launches Hulio (biosimilar, adalimumab) in Canada

Viatris Launches Hulio (biosimilar, adalimumab) in Canada

Shots:

  • Health Canada has approved Hulio, a biosimilar referencing AbbVie’s Humira (adalimumab), which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab indications
  • The approval was based on an analytical, pre/ clinical program. Fujifilm Kyowa Kirin conducted a P-III ARABESC study that demonstrated no differences in terms of safety, efficacy, and immunogenicity compared to its reference product in patients with RA
  • Fujifilm Kyowa Kirin and Viatris aims to expand patient access to more affordable biosimilar medicines across the globe, including in Canada

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Vaitris

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post